
Oracle, Dell, SAP: Premarket Trading
(Pre-market story updated with stock price changes and Tyson Foods fourth-quarter earnings)
NEW YORK (TheStreet) -- Tyson Foods stock was volatile in pre-market trading Monday, falling 2.8% to $15.20 Monday after the company said it expected higher raw-material costs, including those of grain in fiscal 2011, which it plans to offset with operational and pricing improvements. Shortly afterwards, the stock bounced back, rising 2.3% to $16.
The company swung to profit in the fourth quarter, reporting net income of $213 million, or 57 cents a share, from a loss of $457 million, or $1.23 the previous year, partly driven by higher pricing in the pork and prepared foods segments. Excluding an impairment charge of 7 cents related to its Brazil poultry operations, earnings were 64 cents a share, beating the Wall Street consensus estimate of 56 cents a share.
Sales rose by about 3% to $7.44 billion from $7.21 billion the previous year, below the consensus $7.75 billion target.
Regeneron Pharmaceuticals
(REGN) - Get Report
and
Bayer HealthCare
announced on Monday that their VEGF Trap-Eye drug for patients with age-related eye degeneration problems successfully met requirements in two advanced studies of the drug.
Regeneron Pharmaceuticals fell 1.2% to $24.67 at the closing bell Friday.
According to the Wall Street Journal,
Oracle
(ORCL) - Get Report
has been having difficulty tracking down
Hewlett-Packard's
(HPQ) - Get Report
new CEO Leo Apotheker to testify in Oracle's copyright infringement lawsuit against
SAP AG
(SAP) - Get Report
, of which Apotheker was the former CEO.
SAP stock fell by 0.7% to $49.64 in premarket trading, and **Hewlett-Packard shares were rising by 0.5% to $42.70. Oracle finished Friday's trading session down 0.6% to $28.15.
Genzyme
(GENZ)
is mulling over a new deal structure as it tries to break an acquisition deadlock with
Sanofi-Aventis
(SNY) - Get Report
, according to the
Wall Street Journal
. The
Journal
is reporting that the new deal structure would reward shareholders with additional benefits depending on whether the acquired company reaches certain milestones.
Shares of Sanofi-Aventis are up 1.3% to $34.57 in premarket trading. Genzyme stock finished Friday's closing session up 1.5% at $71.31.
Last Thursday, court documents unsealed amid a three-year old lawsuit against Dell raised questions about how the company dealt with a record number of problematic computers sold to governments, schools and companies between 2003 and 2005, according to the
New York Times
. The documents were connected to a lawsuit filed by
Advanced Internet Technologies
alleging Dell of covering up the defects in its desktop computer, the
Times
reported. Shares of Dell are down 0.5% to $13.83 in pre-market trading.
RELATED STORIES:
-- Written by Andrea Tse in New York.
>To contact the writer of this article, click here:
Andrea Tse
.
>To follow the writer on Twitter, go to
.
>To submit a news tip, send an email to:
.
>> Genzyme Mulls New Sanofi Deal Structure
>> Stock Futures Fall on Irish Bailout
>> Heinz, Salesforce, Dell: Premarket Trading
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.









